Eliem Therapeutics PE Ratio 2021-2024 | CLYM
Current and historical p/e ratio for Eliem Therapeutics (CLYM) from 2021 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Eliem Therapeutics PE ratio as of October 03, 2024 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Eliem Therapeutics PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2024-10-03 |
5.10 |
|
0.00 |
| 2024-03-31 |
2.74 |
$-0.53 |
0.00 |
| 2023-12-31 |
2.70 |
$-1.31 |
0.00 |
| 2023-09-30 |
2.63 |
$-1.47 |
0.00 |
| 2023-06-30 |
2.80 |
$-3.13 |
0.00 |
| 2023-03-31 |
2.90 |
$-3.31 |
0.00 |
| 2022-12-31 |
3.67 |
$-3.03 |
0.00 |
| 2024-06-30 |
7.11 |
$-3.24 |
0.00 |
| 2022-09-30 |
3.23 |
$-1.83 |
0.00 |
| 2022-06-30 |
3.02 |
$-2.16 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.342B |
$0.000B |
|
Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.
|
